Using a novel approach with a unique mechanism of action that involves axonal regeneration and modulating the neuroinflammation, Neuroscientific Biopharmaceuticals (ASX: NSB) have developed an advanced preclinical drug candidate with multiple therapeutic indications.
We believe that Neuroscience and Neurodegenerative Diseases hold the most promise for medical breakthrough in the next decade.
The Company recently reported breakthrough data suggesting that we could bring disease modifying therapy to treat Alzheimer’s Disease. We also demonstrated significant promise of our lead product in development in several other neurodegenerative diseases including Multiple Sclerosis, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Spinal Injury and Optic Neuropathies.
Continuously innovating with focus and integrity
A pipeline of potential therapeutic candidates with strong IP protection, backed up by an experienced board and management team, validated strategy and business model and strong strategic partnerships geared towards success.